POLY MEDICURE LIMITED Fair Value
POLYMED · Healthcare · Current price ₹1,759
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹302 | 11% ROE fading to 12% over ~10 yrs, on ₹306 book |
| Relative P/E | ₹2,056 | EPS × 64.7 peer-median P/E |
| Graham floor | ₹468 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹1,910 | Street consensus 12-month target price |
Is POLY MEDICURE LIMITED undervalued?
DocStoX estimates the fair value of POLY MEDICURE LIMITED at ₹1,017 per share, versus the current market price of ₹1,759. That puts the stock about -42.2% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹302), Relative P/E (₹2,056), Graham floor (₹468), Analyst target (₹1,910). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹302 (bear) to ₹1,017 (base) to ₹2,056 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on POLY MEDICURE LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.